EUVIMEDEUVIMED entdecken
Crossref

Personalized Multi‐Epitope Nanovaccine Unlocks B Cell‐Mediated Multiple Pathways of Antitumor Immunity

Wenlu Yan, Ying Cao, Shanshan Xu, Yu Li, Ting Wu, Wenhui Yuan, Qi Yin, Yaping Li iD

Advanced Materials · 2025-02 · 37 (6)

DOI: 10.1002/adma.202411361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 23.12.2024. Verfasst von Wenlu Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203,…. Hauptthemen laut MEDLINE: B-Lymphocytes, Cancer Vaccines, Epitopes, Nanoparticles. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Shandong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B lymphocytes have emerged as an important immune‐regulating target. Inoculation with tumor cell membrane‐derived vaccines is a promising strategy to activate B cells, yet their efficiency is limited due to lack of costimulatory molecules. To amplify B cell responses against tumor, herein, a spatiotemporally‐synchronized antigen‐adjuvant integrated nanovaccine, termed as CM‐CpG‐aCD40, is constructed by conjugating the immune stimulative CpG oligonucleotide and the anti‐CD40 antibody (aCD40) onto the membrane vesicles derived from triple negative breast cancer cells. CM‐CpG‐aCD40 actively accumulates in lymph nodes and is effectively captured by antigen‐presenting cells via the recognition of CD40 by aCD40. Tumor antigens on CM‐CpG‐aCD40 bind to B cell receptors, providing the first stimulation signal for B cells. Meanwhile, the interaction between CpG/Toll like receptor and aCD40/CD40 provides superposed co‐stimulation signals, improving the antibody‐secreting and antigen‐presenting abilities of B cells. The nanovaccine also stimulates dendritic cells to activate CD8 + T cells, and reprograms tumor associated macrophages. CM‐CpG‐aCD40 activating humoral, cellular, and innate antitumor immunity achieves a tumor inhibition rate of 89.3%, which is further improved to 95.4% when combined with the anti‐programmed death ligand 1 (PD‐L1) antibody. CM‐CpG‐aCD40, as a personalized multi‐epitope nanovaccine, paves the way for ushering the era of B cell‐based immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B-LymphocytesCancer VaccinesEpitopesNanoparticlesAnimalsHumansCD40 AntigensMiceCell Line, TumorOligodeoxyribonucleotidesFemaleCD8-Positive T-LymphocytesAdjuvants, ImmunologicDendritic CellsNanovaccines

Stichwörter der Autor:innen

B lymphocytescellular immunityhumoral immunitynanovaccinetumor immunotherapy

Substanzen

Cancer VaccinesCD40 AntigensEpitopesOligodeoxyribonucleotidesCPG-oligonucleotideAdjuvants, ImmunologicNanovaccines

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • School of Pharmacy, University of Chinese Academy of Sciences, Beijing, 100049, China.
  • School of Life Sciences, Jilin University, Changchun, 130012, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211116, China.
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Yantai, 264000, China.

ORCID-Profile: Yaping Li

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong
  • Shandong Laboratory Program
  • National Key Research and Development Program of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Yan, W., Cao, Y., Xu, S., Li, Y., Wu, T., Yuan, W., Yin, Q., & Li, Y. (2025). Personalized Multi‐Epitope Nanovaccine Unlocks B Cell‐Mediated Multiple Pathways of Antitumor Immunity. Advanced Materials, 37(6). https://doi.org/10.1002/adma.202411361

Vancouver

Yan W, Cao Y, Xu S, Li Y, Wu T, Yuan W, et al. Personalized Multi‐Epitope Nanovaccine Unlocks B Cell‐Mediated Multiple Pathways of Antitumor Immunity. Advanced Materials. 2025;37(6). doi:10.1002/adma.202411361

BibTeX
@article{Yan2025,
  author = {Yan, Wenlu and Cao, Ying and Xu, Shanshan and Li, Yu and Wu, Ting and Yuan, Wenhui and Yin, Qi and Li, Yaping},
  title = {Personalized Multi‐Epitope Nanovaccine Unlocks B Cell‐Mediated Multiple Pathways of Antitumor Immunity},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {6},
  doi = {10.1002/adma.202411361}
}
Kostenlos starten →